Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Active, not recruiting
Actelion
Phase 2
2010-05-01
This study is an extension to the study AC-058B201 and will investigate the long-term safety,
tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple
sclerosis.
Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects
Completed
Actelion
Phase 1
2014-08-01
This study consists of a single-dose pilot phase and a randomized, two-way crossover,
single-dose main phase.The aim of this study is to evaluate the absolute bioavailability of
the oral formulation (tablet) of ponesimod compared to an intravenous (i.v.) ponesimod
formulation. Three subjects will be included in the pilot phase and 12 subjects in the main
crossover phase.
Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects
Completed
Actelion
Phase 1
2011-08-01
The aim of this study is to demonstrate that therapeutic and supratherapeutic plasma
exposures to ponesimod do not have an effect on cardiac repolarization exceeding the
threshold of regulatory concern as measured by the QTc (interval from beginning of the Q wave
until end of the T wave corrected for heart rate) interval duration after administration of
multiple oral doses of 40 mg and 100 mg to healthy male and female subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
